The ever-advancing science of bone grafting propels innovations, guided by experience, skills, and leadership.
FREMONT, CA:Cerapedics, an ortho-biologics company, appoints Patrick O’Connor as the Vice President of clinical and market development. “We are pleased to welcome Mr. O’Connor to the Cerapedics team as we continue to enroll patients in our investigational device exemption (IDE) clinical trial evaluating the safety and efficacy of the next-generation P-15L Peptide Enhanced Bone Graft in transforaminal lumbar interbody fusion (TLIF) surgery,” says Dr. Jeffery G. Marx, Ph.D., president and Chief Operating Officer of Cerapedics.
Patrick O’Connor, former director of market development for Spinal Kinetics, an orthofix company, carries experiences in patient education efforts and working knowledge with the surgeons to support clinical trial enrolment and market development. O’Connor's expertise in the medical instrument and surgery fields delivers valuable insights to Cerapedics. “He brings a proven track record leading the successful coordination of IDE trials, including developing important surgeon relationships and executing effective publication strategies. We look forward to his insights and believe his experience will support us not only in the near-term, but also as we look to develop the lumbar market in the years ahead,” Jeffery continues.
Cerapedics, featured in MedTech Outlook as one of the Top 10 Orthopedic Solution Providers, delivers cutting edge products in osteobiologic science also invests in clinical studies for in-depth research. Every year, surgeons face critical decisions of choosing an appropriate bone graft technology. Today, i-Factor- a safe bone formation solution sets new levels in the science of bone repair, registering to be the natural bone graft with premarket approval from the FDA. With this revolutionary, Cerapedics contributes immeasurable values to the medical industry. “Our primary aim is to provide exceptional outcomes and better safety but all at the reasonable cost. We empower clients with a twofold advantage: an evidence-based technology and a price point that fits within the reimbursement landscape,” Jeffery adds.